Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 14, 2024 11:52am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
That's terrible considering it was close to $10 a few years ago...going downhill here
(185)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Nov 14, 2024 9:03am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
DJ Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(479)
•••
Peladawn
X
View Profile
View Bullboard History
Comment by
Peladawn
on Nov 14, 2024 8:32am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
Poor Bucky....he could have made grade 7 if only he hadn't flunked grade 3 four times.
(37)
•••
jimrabbit
X
View Profile
View Bullboard History
Comment by
jimrabbit
on Nov 13, 2024 10:04pm
RE:Immunotherapy
What good news
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 13, 2024 7:24pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
They say that everything should be written on a 7th grade comprehension level... but in the pumpers case I had to go down to 3rd grade level..and even then unnoteable has to help peladuffus comprehend
...more
(2)
•••
TwasAtWitsEnd
X
View Profile
View Bullboard History
Post by
TwasAtWitsEnd
on Nov 13, 2024 7:05pm
Immunotherapy
I think I have identified the villians posting here. I don't remember all the motives of pumpers and dumpers. Volume tends to increase along with price before good news comes out. There was not a
...more
(479)
•••
Peladawn
X
View Profile
View Bullboard History
Comment by
Peladawn
on Nov 13, 2024 4:22pm
RE:RE:RE:RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
Why, Bucky?.....the only thing you're capable of is posting childish garbage on a message board
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 13, 2024 3:36pm
RE:RE:RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
I would say the compassionate blame falls on the company management.. we have no control... they do.. so quit embarrassing yourselves pumpers.
(479)
•••
Peladawn
X
View Profile
View Bullboard History
Comment by
Peladawn
on Nov 13, 2024 2:56pm
RE:RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
Hey Quenty.....your obvious compassion for all the souls afflicted with this horrible disease who are desperately waiting for the hope that pela could bring is overwhelming!...what a douche!
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 13, 2024 2:08pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s News
Reverse split and delisting letter coming soon.
(94)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Nov 13, 2024 2:08pm
RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
Gosh, the market is just loving yesterday's update... look at the stock go bonkers... erm. NO... They CANNOT file for AA ANYTIME as you claim. THEY must have statisically relevant data from two
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 13, 2024 1:58pm
RE:RE:RE:RE:RE:Looming Big Pharma Patent Cliff
A surrogate endpoint used for accelerated approval is a marker. The FDA bases its decision on whether to accept the proposed surrogate or intermediate clinical endpoint on the scientific support
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 13, 2024 1:46pm
RE:RE:RE:RE:Looming Big Pharma Patent Cliff
ONCY can file for an Accelerated Approval at anytime on basis of the surrogate endpoints it has reported on in the Bracelet-1 Phase-2 mBC clinical trial. Those now confirmed surrogate endpoints are
...more
(216)
•••
13X2413
X
View Profile
View Bullboard History
Comment by
13X2413
on Nov 13, 2024 1:27pm
RE:RE:RE:Looming Big Pharma Patent Cliff
As of September 30, 2024, the Company reported $19.6 million in cash and cash equivalents. The Company has a projected cash runway through key milestones and into 2025. They better
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden